Orthocell Limited
OCC.ASXHealth Care
Regenerative medicine sector for chronic degenerative diseases and injury.
Market Data
$0.780
+0.0%$208.3M
-100000.0x
$-0.053
0.00%
-0.3%
Latest Earnings
Appendix 4D & Half-Year Financial Report
24 February 2026
Orthocell Limited delivered a record first half of FY26 with revenue up 48% to $6.2M and strong gross margin improvement to 55%. Despite increased losses of $5.2M due to planned US expansion investments, the company is well-capitalised with $49.4M in cash following a $30M capital raise. The US commercial launch is progressing to plan with Remplir™ approved in 45 states and growing hospital account adoption. Key points: Record revenue of $6.2M, up 48% with two consecutive record quarters; Gross margin expanded to 55% from 50%, driven by efficiencies and higher-margin Remplir™ sales; US commercial launch on track with 45 state approvals, 27 hospital VAC approvals, and 19 active accounts
Recent Announcements
Appendix 4D & Half-Year Financial Report
Orthocell Limited delivered a record first half of FY26 with revenue up 48% to $6.2M and strong gross margin improvement to 55%. Despite increased losses of $5.2M due to planned US expansion investments, the company is well-capitalised with $49.4M in cash following a $30M capital raise. The US commercial launch is progressing to plan with Remplir™ approved in 45 states and growing hospital account adoption. Key points: Record revenue of $6.2M, up 48% with two consecutive record quarters; Gross margin expanded to 55% from 50%, driven by efficiencies and higher-margin Remplir™ sales; US commercial launch on track with 45 state approvals, 27 hospital VAC approvals, and 19 active accounts
Get real-time alerts for OCC
Receive AI-powered earnings summaries and instant notifications when Orthocell Limited releases results.
Register Free